KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Current Deferred Revenue: 2021-2024

Historic Current Deferred Revenue for Travere Therapeutics (TVTX) over the last 3 years, with Dec 2024 value amounting to $2.8 million.

  • Travere Therapeutics' Current Deferred Revenue fell 68.48% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year decrease of 68.48%. This contributed to the annual value of $2.8 million for FY2024, which is 68.48% down from last year.
  • As of Q4 2024, Travere Therapeutics' Current Deferred Revenue stood at $2.8 million, which was down 25.90% from $3.8 million recorded in Q3 2024.
  • In the past 5 years, Travere Therapeutics' Current Deferred Revenue registered a high of $36.6 million during Q4 2021, and its lowest value of $2.8 million during Q4 2024.
  • Over the past 3 years, Travere Therapeutics' median Current Deferred Revenue value was $9.6 million (recorded in 2023), while the average stood at $9.9 million.
  • Data for Travere Therapeutics' Current Deferred Revenue shows a maximum YoY crashed of 68.48% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Travere Therapeutics' Current Deferred Revenue stood at $36.6 million in 2021, then tumbled by 37.49% to $22.9 million in 2022, then tumbled by 61.01% to $8.9 million in 2023, then tumbled by 68.48% to $2.8 million in 2024.
  • Its last three reported values are $2.8 million in Q4 2024, $3.8 million for Q3 2024, and $5.4 million during Q2 2024.